Concurrent Chemoradiotherapy with S-1 as First-line Treatment for Patients with Oropharyngeal Cancer
-
- OHNISHI Kayoko
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
-
- SHIOYAMA Yoshiyuki
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
-
- NAKAMURA Katsumasa
- Department of Radiology, Kyushu University Hospital at Beppu
-
- NAKASHIMA Torahiko
- Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University
-
- OHGA Saiji
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
-
- NONOSHITA Takeshi
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
-
- YOSHITAKE Tadamasa
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
-
- TERASHIMA Kotarou
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
-
- KOMUNE Shizuo
- Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University
-
- HONDA Hiroshi
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
この論文をさがす
抄録
Purpose: S-1 is an oral fluoropyrimidine. The purpose of this study was to review the clinical outcomes of S-1 with concurrent radiotherapy for patients with oropharyngeal cancer. Materials and Methods: Between 2002 and 2007, 38 patients with oropharyngeal cancer treated concurrently with S-1 and definitive radiotherapy were reviewed. The clinical stage was Stage I in 4 patients, Stage II in 7, Stage III in 7, and Stage IV in 20. S-1 was administered orally twice daily for 4 consecutive weeks followed by a 2-week drug withdrawal. The initial dose of S-1 was 65 mg/m2/day. All patients were treated using three-dimensional conformal radiotherapy with a median total dose of 65.1 Gy (range, 60.0–71.0 Gy). Clinical outcomes and major acute toxicities were analyzed based on medical records and clinical follow-up. Results: With a median follow-up time of 33 months, the 3-year estimates of local-regional control, distant metastases-free survival, disease-free survival, and overall survival for all patients were 75%, 80%, 65%, and 80%, respectively. The 3-year estimates of local-regional control according to stage were 100% for Stages I and II, 86% for Stage III, and 56% for Stage IV. The rate of ≥ Grade 3 acute mucositis was 32%, and the rate of ≥ Grade 3 hematological toxicities was 8%. No other severe toxicities were observed. Conclusions: Concurrent chemoradiotherapy with S-1 was found to be effective, especially for early disease. The treatment-related toxicities were acceptable, and the incidence of myelotoxicity was low. Further study must be carried out to compare with other chemotherapy regimens.
収録刊行物
-
- Journal of Radiation Research
-
Journal of Radiation Research 52 (1), 47-53, 2011
Journal of Radiation Research 編集委員会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282680194289408
-
- NII論文ID
- 10027418232
-
- NII書誌ID
- AA00705792
-
- ISSN
- 13499157
- 04493060
-
- NDL書誌ID
- 10953730
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可